Dr Reddy's launches Atocor-R in India

MUMBAI: Pharmaceutical major Dr Reddy's Laboratories on Thursday announced the launch of a drug 'Atocor-R', a combination of Atorvastatin and Ramipril, used in the treatment of cardiavascular disease, in the domestic market.

Atocor-R is the first such combination to be approved by Drug Controller General of India (DCGI) and has already completed a multicentre clinic trial data on Indian patients, Dr Reddy's said in a filing to Bombay Stock Exchange.

Atorvastatin is a world largest cholesterol lowering drug and Ramipril is a proven cardioprotective agent and these two drugs have a combined domestic market of around Rs 450 crore per annum.

The combination of these two blockbuster molecules  Atocor-R  is particularly used in the treating patients with both essential hypertension and hypercholesterolemia, the company said.

Dr Reddy's is a Hyderabad-based vertically integrated pharmaceutical company.